PDF(Pubmed)
Abstract：
Bladder cancer (BC) is the 10th most common cancer worldwide, with about 0.5 million reported new cases and about 0.2 million deaths per year. In this scoping review, we summarize the current evidence regarding the clinical implications of single-cell sequencing for bladder cancer based on PRISMA guidelines. We searched PubMed, CENTRAL, Embase, and supplemented with manual searches through the Scopus, and Web of Science for published studies until February 2023. We included original studies that used at least one single-cell technology to study bladder cancer. Forty-one publications were included in the review. Twenty-nine studies showed that this technology can identify cell subtypes in the tumor microenvironment that may predict prognosis or response to immune checkpoint inhibition therapy. Two studies were able to diagnose BC by identifying neoplastic cells through single-cell sequencing urine samples. The remaining studies were mainly a preclinical exploration of tumor microenvironment at single cell level. Single-cell sequencing technology can discriminate heterogeneity in bladder tumor cells and determine the key molecular properties that can lead to the discovery of novel perspectives on cancer management. This nascent tool can advance the early diagnosis, prognosis judgment, and targeted therapy of bladder cancer.
摘要：
膀胱癌（BC）是全球第10大最常见的癌症，每年报告约50万新病例，约20万人死亡。在这次范围审查中，我们根据PRISMA指南总结了目前有关膀胱癌单细胞测序临床意义的证据.我们搜索了PubMed,中部,Embase,并通过Scopus进行手动搜索，和WebofScience发表的研究直到2023年2月。我们纳入了使用至少一种单细胞技术研究膀胱癌的原始研究。审查中包括41种出版物。29项研究表明，这项技术可以识别肿瘤微环境中可能预测预后或对免疫检查点抑制治疗反应的细胞亚型。两项研究能够通过单细胞测序尿液样品鉴定肿瘤细胞来诊断BC。其余研究主要是在单细胞水平上对肿瘤微环境的临床前探索。单细胞测序技术可以区分膀胱肿瘤细胞中的异质性，并确定可以导致发现癌症管理新观点的关键分子特性。这个新生的工具可以推进早期诊断，预后判断,和膀胱癌的靶向治疗。
